Memorial Sloan Kettering Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Memorial Sloan Kettering Cancer Center sits in the top decile of US sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count).
Memorial Sloan Kettering Cancer Center: 1,884 sponsored US clinical trials, 327 recruiting.
Memorial Sloan Kettering Cancer Center sponsors 1,884 registered US clinical trials on ClinicalTrials.gov, 327 of them currently recruiting, and 1,104 completed. 75 of these trials are in Phase 3-4 (later-stage) and 1,101 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 98 trials.
Top-decile sponsor footprint
Memorial Sloan Kettering Cancer Center ranks in the top decile of sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
1,884 total, page 34 of 38
Taurolidine in Treating Patients With Recurrent or Progressive Glioma
NCT00022360
TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00022347
Immediate Vaginal Reconstruction After Oncologic Resection: Surgical Outcomes, Patient Satisfaction and Sexual Function
NCT00588081
Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma
NCT00027742
PS-341 in Treating Patients With Metastatic Kidney Cancer
NCT00017329
Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00022256
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
NCT00024258
Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence
NCT00030823
Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00021034
CT Scans in Guiding the Treatment of Patients With Prostate Cancer Who Are Undergoing Radiation Therapy
NCT00020891
Cetuximab in Treating Patients With Stage IV Colorectal Cancer
NCT00020930
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
NCT00027638
BMS-247550 in Treating Women With Metastatic Breast Cancer
NCT00020904
CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer
NCT00017017
BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy
NCT00017056
Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer
NCT00020917
Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma
NCT00017030
Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer
NCT00016224
ZD 1839 in Treating Patients With Metastatic Kidney Cancer
NCT00012337
Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed
NCT00040898
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer
NCT00014469
Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation
NCT00014482
Magnetic Resonance Imaging and Spectroscopy of the Prostate
NCT00590993
SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck
NCT00006361
Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer
NCT00016250
PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus
NCT00016900
Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer
NCT00579423
ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00016172
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer
NCT00014495
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
NCT00016159
Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver
NCT00012155
Huang Lian (Chinese Herb) in Treating Patients With Advanced Solid Tumors
NCT00014378
Ro 31-7453 in Treating Patients With Metastatic Solid Tumors
NCT00014365
Celecoxib in Treating Patients With Precancerous Lesions of the Mouth
NCT00014404
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
NCT00014352
Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
NCT00006380
Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors
NCT00006485
Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum
NCT00012090
Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment
NCT00008359
Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma
NCT00008242
INS316 in Diagnosing Lung Cancer in Patients With Untreated Lung Cancer
NCT00008255
Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
NCT00008294
Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer
NCT00695201
Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma
NCT00008268
Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel
NCT00006245
Cognitive Functioning and Quality of Life in CNS Lymphoma
NCT00581737
Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer
NCT00016146
Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer
NCT00006377
Multiple Therapies in Treating Patients With Advanced Neuroblastoma
NCT00040872
Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer
NCT00006381
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 461 |
| Phase 2 | 640 |
| Phase 3 | 67 |
| Phase 4 | 8 |
Therapeutic Areas
What is open in the Memorial Sloan Kettering Cancer Center pipeline
327 recruiting of 1,884 indexed (17% open); 1,104 completed (59%).
Phase mix: 75 late (III/IV) vs 1,101 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (98 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.